Regentis Biomaterials Expands SAGE Trial of GelrinC

Regentis Biomaterials expanded the SAGE clinical trial of GelrinC™ to 11 U.S. sites, comparing the device to microfracture in the treatment of damaged articular knee cartilage.

SAGE is an FDA Investigational Device Exemption multi-center Phase III pivotal study that will enroll 120 patients. GelrinC contains synthetic polyethylene glycol...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0